

Supplemental Materials for “The specter of Manaus: the risks of a rapid return to pre-pandemic conditions after COVID-19 vaccine rollout”

Supplemental Methods

Detailed S-I-R model description

To investigate SARS-CoV-2 infection dynamics and evolution after vaccine deployment, we built a deterministic susceptible-infected-recovered (S-I-R) epidemiological model that explicitly accounts for the spread of existing variants. The simplest S-I-R model we used has two competing viral genotypes circulating in the population: wild-type (WT) and variant SARS-CoV-2 (Fig. 1A). This model has separate infected and recovered compartments for individuals with WT and variant infections. Importantly, vaccination and infection with WT virus completely protects individuals from infection with WT virus, but only provides partial protection from variant infection. This overestimates vaccine efficacy against WT SARS-CoV-2, as the most effective vaccines (the mRNA vaccines deployed widely in the US) have been shown to be approximately 95% effective against infection [1].

The model equations are

$$\begin{aligned} \frac{dS}{dt} &= \rho(R + R_m + V) - (\beta I + \beta\alpha_m I_m + z)S \\ \frac{dV}{dt} &= zS - (\rho + \beta(1 - c)\alpha_m I_m)V \\ \frac{dI}{dt} &= \beta SI - \gamma I \\ \frac{dI_m}{dt} &= (S + (1 - c)(R + V))\beta\alpha_m I - \gamma I_m \\ \frac{dR}{dt} &= \gamma I - (\rho + \beta\alpha_m(1 - c)I)R \\ \frac{dR_m}{dt} &= \gamma I_m - \rho R_m \end{aligned}$$

where S and V correspond to the fractions of the population who are susceptible and vaccinated, respectively, with susceptible individuals receiving the vaccine at rate z . I_w and I_m represent the fraction of individuals who are currently infected with WT or variant SARS-CoV-2, respectively. These infected individuals eventually recover at rate γ and enter the recovered compartments, R_w and R_m . Susceptible individuals are infected with WT virus at a rate proportional to the contact rate β . The variant infects susceptible individuals with an effective contact rate $\beta\alpha_m$, where α_m is the variant’s transmission advantage relative to WT. Note that there is a relationship between the contact rate β , the recovery period length, and the basic reproductive number R_0 of the WT virus; namely, $\beta = \gamma R_0$. Vaccinated individuals and those who have recovered from WT infection are partially protected from variant infection and are infected at rate proportional to $\beta\alpha_m(1 - c)$, where $c < 1$ is the degree of protection from variant infection conferred by WT immunity. Individuals who have recovered from the variant infection cannot be reinfected with either the WT or variant virus. Both vaccinal and natural immunity are lost at rate ρ .

This S-I-R modeling framework was expanded to include multiple competing SARS-CoV-2 variants. In the more general case, there are n SARS-CoV-2 variants competing against each other and the WT virus. There are in total $n + 1$ infected and $n + 1$ recovered compartments, each corresponding to

a specific viral genotype. Defining \vec{I} and \vec{R} as the vectors of frequencies of individuals infected and recovered from each viral genotype, we have

$$\begin{aligned}\frac{dS}{dt} &= \rho \sum R_i - zS - (\vec{I} \cdot \mathbf{B}_S)S \\ \frac{dV}{dt} &= zS - \rho V - (\vec{I} \cdot \mathbf{B}_V)V \\ \frac{d\vec{I}}{dt} &= (\mathbf{B}^T \mathbf{A}) \odot \vec{I} - \gamma \vec{I} \\ \frac{d\vec{R}}{dt} &= \gamma \vec{I} - \rho \vec{R} - \mathbf{B}_R \vec{R}^T \odot \vec{I}\end{aligned}$$

where \odot denotes element-wise multiplication. The contact rate matrix \mathbf{B} describes the transmissibilities and cross infection potentials of the variants in the simulation, and has $n + 3$ rows corresponding to each of the non-infected compartments (S , V , and \vec{R}) and $n + 1$ columns corresponding to the infected compartments. Each entry $b_{i,j}$ denotes the rate at which infected compartment j can infect individuals in compartment i . More specifically,

$$\mathbf{B} = \beta \begin{pmatrix} 1 & \alpha_1 & \dots & \alpha_n \\ 0 & \alpha_1 c_{0,1} & \dots & \alpha_n c_{0,n} \\ 0 & \alpha_1 c_{0,1} & \dots & \alpha_n c_{0,n} \\ c_{1,0} & \alpha_1 c_{1,1} & \dots & \alpha_n c_{1,n} \\ \vdots & \vdots & \ddots & \vdots \\ c_{n,0} & \alpha_1 c_{n,1} & \dots & \alpha_n c_{n,n} \end{pmatrix}$$

where α_i is the transmission advantage of variant i and $c_{i,j}$ is the cross immunity to infection with variant j conferred by previous infection with variant i , where variant 0 is WT. The first row (also defined as \mathbf{B}_S) corresponds to the rates at which the WT and variants infect susceptible individuals. Similarly, the second row (also defined as \mathbf{B}_V) corresponds to the rates at which the WT and variants infect vaccinated individuals. The remaining rows of this matrix are defined as \mathbf{B}_R , and corresponds to the rates at which the WT and variants infect recovered individuals. The cross immunity relationships shown in Fig. 2A were used to populate the entries of \mathbf{B} . The column vector \mathbf{A} has entries $a_1 = S$, $a_2 = V$, and $a_{i+2} = R_i$ for $i = 0, \dots, n$.

To simulate both versions of the model, the above systems of differential equations were numerically solved using `scipy.integrate` (version 1.4.1) in Python. Parameter values, initial conditions, and references used for the simulations are provided in Tables S1 and S2.

Estimation of total fatalities due to COVID-19

The total number of deaths due to COVID-19 during the first year after the starting point of the simulations was estimated by using the simulation results to calculate the number of COVID-19 cases occurring in previously unexposed or previously-infected/vaccinated individuals separately. Individuals who were not previously exposed to SARS-CoV-2 were assumed to have an infection fatality rate (IFR) of 0.68% [2]. We estimated the IFR for vaccinated/immune individuals relative to unexposed individuals as $\frac{1 - \text{IRR}_{\text{vac}}}{1 - \text{IRR}_{\text{unvac}}}$, where IRR is the infection rate ratio, as measured in [3]. This corresponds to an IFR for vaccinated and previously-infected individuals of 0.48%.

Supplemental Tables

Table S1. Parameter values for transmissibility and cross immunity for SARS-CoV-2 variants.

Variant	Transmissibility relative to WT	Trans. reference	Vaccine or WT immune efficacy	Immunity reference	% of US infections as of 4/10/21
B.1.1.7	1.59	[4]	89.5%	[5]	59.6%
B.1.351	1.5	[6]	75.0%	[5]	1.0%
P.1	2.0	[7]	68.0%	[7]	3.7%

All variant frequency data was taken from the CDC COVID Data Tracker [8].

Table S2. Other parameter values used to simulate SARS-CoV-2 spread.

Parameter	Value	Reference
Initial fraction of population vaccinated	50%	[9]
Daily vaccine uptake rate (% susceptibles vaccinated/day)	1%	[9] (upper bound)
Initial fraction of population previously infected	30%	[10]
Initial fraction of population currently infected	0.13%	$\frac{(\text{current case count})(\text{mean infection duration})}{\text{total US population}}$
Mean infection duration	10 days	[11]
Mean duration of immunity	18 months	[12] (upper bound)
R_0 of WT SARS-CoV-2	3.32	[13]
Total population size	300 million	approximate size of US population

Supplemental References

1. Pilishvili, T. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021. en-us. *MMWR Morb Mortal Wkly Rep* **70**. ISSN: 0149-21951545-861X. <https://www.cdc.gov/mmwr/volumes/70/wr/mm7020e2.htm> (2021) (2021).
2. Meyerowitz-Katz, G. & Merone, L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. en. *International Journal of Infectious Diseases* **101**, 138–148. ISSN: 1201-9712. <https://www.sciencedirect.com/science/article/pii/S1201971220321809> (2021) (Dec. 2020).
3. Haas, E. J. *et al.* Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. English. *The Lancet* **0**. Publisher: Elsevier. ISSN: 0140-6736, 1474-547X. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00947-8/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-8/abstract) (2021) (May 2021).
4. Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. en. *Science*. Publisher: American Association for the Advancement of Science Section: Research Article. ISSN: 0036-8075, 1095-9203. <https://science.sciencemag.org/content/early/2021/03/03/science.abg3055> (2021) (Mar. 2021).
5. Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine* **0**. Publisher: Massachusetts Medical Society _eprint: <https://doi.org/10.1056/NEJMc2104974>, null. ISSN: 0028-4793. <https://doi.org/10.1056/NEJMc2104974> (2021) (May 2021).
6. Pearson, C. A. B. *et al.* Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa en. Jan. 2021. <https://cmmid.github.io/topics/covid19/sa-novel-variant.html> (2021).
7. Faria, N. R. *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. en. *Science*. Publisher: American Association for the Advancement of Science Section: Research Article. ISSN: 0036-8075, 1095-9203. <https://science.sciencemag.org/content/early/2021/04/13/science.abh2644> (2021) (Apr. 2021).
8. CDC. *COVID Data Tracker* en. <https://covid.cdc.gov/covid-data-tracker> (2021).
9. *U.S. COVID-19 vaccine tracker: See your state's progress* en. <https://www.mayoclinic.org/coronavirus-covid-19/vaccine-tracker> (2021).
10. CDC. *Cases, Data, and Surveillance* en-us. Feb. 2020. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html> (2021).
11. Rocklöv, J., Sjödin, H. & Wilder-Smith, A. COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures. eng. *J Travel Med* **27**. ISSN: 1708-8305 (May 2020).
12. Isho, B. *et al.* Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. en. *Science Immunology* **5**. Publisher: Science Immunology Section: Research Article. ISSN: 2470-9468. <https://immunology.sciencemag.org/content/5/52/eabe5511> (2021) (Oct. 2020).
13. Alimohamadi, Y., Taghdir, M. & Sepandi, M. Estimate of the Basic Reproduction Number for COVID-19: A Systematic Review and Meta-analysis. *J Prev Med Public Health* **53**, 151–157. ISSN: 1975-8375. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280807/> (2021) (May 2020).